Welcome to our dedicated page for Nanobiotix S.A. American Depositary Shares news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix S.A. American Depositary Shares stock.
Nanobiotix S.A. (Euronext: NANO / ISIN: FR0011341205) is a leading clinical-stage nanomedicine company specializing in the development of groundbreaking approaches for cancer treatment. The company's core technology, NanoXray, augments the effectiveness of radiotherapy, offering a more efficient treatment option for cancer patients. The innovative NanoXray products are designed to be compatible with existing radiotherapy treatments and aim to treat a broad spectrum of solid tumors, such as soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma.
The primary product candidate, NBTXR3, is currently undergoing evaluation for its efficacy in treating soft tissue sarcoma, head and neck cancers, prostate cancer, and liver cancers (both primary and metastases). Additionally, Nanobiotix has partnered with PharmaEngine in Taiwan to conduct trials for head and neck cancer and rectal cancer in the Asia Pacific region.
Nanobiotix has also embarked on a preclinical research program in immuno-oncology, further expanding its portfolio and potential for transformative cancer therapies. NBTXR3 works by magnifying the effects of radiotherapy within tumor cells, thereby enhancing cancer treatment without increasing the dose to surrounding healthy tissues.
Recently, Nanobiotix has been focused on validating the safety and efficacy of RT-activated NBTXR3 by moving to global registration for LA-HNSCC, accounting for the majority of its operational and financial resources. The company plans to provide an updated global development plan for NBTXR3 after further alignment with the Joint Steering Committee (JSC).
In terms of financial performance, Nanobiotix has laid out a cautious strategy, ensuring that it remains well-funded to support ongoing and future operations. Their forward-looking statements highlight the potential risks and uncertainties that could affect their business and financial performance.
For the latest updates, Nanobiotix has scheduled a conference call and webcast on May 22, 2024, at 8:00 am EDT / 2:00 pm CEST. It continues to engage the market, providing transparency to shareholders through various media and regular updates on their progress and milestones.
To keep up with the latest news, visit www.nanobiotix.com.
Nanobiotix has announced significant milestones regarding its pivotal Phase III study, NANORAY-312, for advanced head and neck cancer, aiming for US site activation in Q3 2022. The company has received FDA feedback on a Phase III protocol for NBTXR3 in combination with anti-PD-1 therapy, with submission targeted for Q1 2023. As of March 31, 2022, Nanobiotix reported a cash position of €70.6 million. The company is implementing strategies to reduce operating expenses and has established an equity financing line to extend its financial runway into Q4 2023, while also exploring debt restructuring options.
Nanobiotix (Euronext: NANO – NASDAQ: NBTX), a late-stage biotechnology company focused on cancer treatment, announced participation in the Jefferies Healthcare Conference on June 8, 2022, at 1:00 PM ET. Laurent Levy, co-founder and chairman, and Bart Van Rhijn, CFO, will present at the event. A live webcast and replay will be available on the company's website. Founded in 2003 and headquartered in Paris, Nanobiotix specializes in physics-based therapeutic innovations.
NANOBIOTIX, a clinical-stage biotechnology company, announced participation in two upcoming conferences: the UBS Global Healthcare Conference on May 23, 2022, at 10:45 AM ET in New York, and the H.C. Wainwright Global Investment Conference on May 25, 2022, at 8:30 AM ET, available virtually and in Miami, Florida. Live webcasts will be accessible via the company’s events page, with replays available within 48 hours. NANOBIOTIX focuses on innovative cancer treatments, particularly their lead product, NBTXR3.
Nanobiotix (Nasdaq: NBTX) announced its total number of voting rights as of April 30, 2022. The company has 34,875,872 shares outstanding. The total voting rights, gross, stand at 36,392,064, while the net voting rights count is 36,371,073. These figures are disclosed in compliance with the French Commercial Code and regulations from the Autorité des Marchés Financiers.
Nanobiotix is set to announce its financial results for Q1 2022 on May 18, 2022, after the US market closes. A conference call will follow on May 19, 2022, at 8 AM EDT, where CEO Laurent Levy and CFO Bart Van Rhijn will discuss results and updates on operations. The company, known for its innovative cancer treatment NBTXR3, is advancing clinical studies, particularly in head and neck cancer. NBTXR3 has received Fast Track designation from the FDA, highlighting its potential in oncology.
Nanobiotix announced the presentation of three abstracts for its first-in-class radioenhancer NBTXR3 at the 2022 ASCO Annual Meeting from June 3-7. CEO Laurent Levy highlighted the aim to improve cancer patient outcomes by validating NBTXR3's safety and efficacy across various treatments. The accepted abstracts cover clinical trials involving head and neck cancer and rectal cancer. NBTXR3 is designed to induce significant tumor cell death when activated by radiotherapy and is currently under evaluation for several indications.
Nanobiotix announced new preclinical data at the 2022 American Association of Cancer Research meeting, showcasing the effectiveness of NBTXR3 in combination with anti-PD-1, anti-LAG-3, and anti-TIGIT therapies. The study indicated that this combination therapy significantly enhanced immune activation, longevity in anti-cancer memory, and overall survival in mice. This suggests potential effectiveness against metastatic cancers, indicating a promising avenue for future clinical applications.
Nanobiotix filed its universal registration document and Annual Report on Form 20-F for the financial year ended December 31, 2021, with the AMF and SEC, respectively. These documents include the annual financial report, corporate governance management report, auditor's reports, and details about the company’s share buyback program. Notably, Nanobiotix's NBTXR3, a novel oncology product, is showing early efficacy signs in clinical trials for advanced head and neck cancer. The company plans future financial updates on May 10, June 21, September 7, and November 9, 2022.
Nanobiotix, listed on Euronext Paris and Nasdaq (NBTX), has reported its outstanding shares as of March 31, 2022, at 34,875,872. The total voting rights stood at 36,317,823 gross and 36,304,866 net. The company is pioneering physics-based therapeutic approaches, notably in oncology with its lead product, NBTXR3, which has secured market authorization in Europe for soft tissue sarcoma treatment under the brand name Hensify®.
For further details, visit www.nanobiotix.com.
FAQ
What is the current stock price of Nanobiotix S.A. American Depositary Shares (NBTX)?
What is the market cap of Nanobiotix S.A. American Depositary Shares (NBTX)?
What is Nanobiotix S.A. known for?
What is NanoXray technology?
What types of cancer does NBTXR3 target?
Who is Nanobiotix partnered with in the Asia Pacific region?
What recent projects are Nanobiotix involved in?
When is the next conference call and webcast scheduled?
How does NBTXR3 enhance radiotherapy?
What is the significance of Nanobiotix’s preclinical research program?
Where can I find more information about Nanobiotix?
